US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
EP0090505B1
(fr)
|
1982-03-03 |
1990-08-08 |
Genentech, Inc. |
Antithrombine III humaine, séquences d'ADN pour celli-ci, vecteurs de clonage et d'expression contenant ces sequences et cultures de cellules transformées par ceux-ci, procédé pour exprimer l'antithrombine III humaine et compositions pharmaceutiques la contenant
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
ATE159009T1
(de)
|
1991-05-10 |
1997-10-15 |
Rhone Poulenc Rorer Int |
Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
JP3560609B2
(ja)
|
1992-11-13 |
2004-09-02 |
イミュネックス・コーポレーション |
Elkリガンドと呼ばれる新規なサイトカイン
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
JPH08503971A
(ja)
|
1993-10-01 |
1996-04-30 |
チバ−ガイギー アクチェンゲゼルシャフト |
ピリミジンアミン誘導体及びその調製のための方法
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
WO1995014023A1
(fr)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
|
EP0734389B1
(fr)
|
1993-12-17 |
2000-03-29 |
Novartis AG |
Derives de rapamycine utilises comme immunosuppresseurs
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(fr)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
|
CA2189028A1
(fr)
|
1994-04-15 |
1995-10-26 |
Gary M. Fox |
Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
|
EP0682027B1
(fr)
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
PT821671E
(pt)
|
1995-04-20 |
2001-04-30 |
Pfizer |
Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
ES2187660T3
(es)
|
1995-06-09 |
2003-06-16 |
Novartis Ag |
Derivados de rapamicina.
|
CA2224435C
(fr)
|
1995-07-06 |
2008-08-05 |
Novartis Ag |
Pyrrolopyrimidines et leurs procedes de preparation
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Hoffmann La Roche |
Matrix-metalloprotease Inhibitoren
|
PT888349E
(pt)
|
1996-01-23 |
2002-10-31 |
Novartis Ag |
Pirrolopirimidinas e processos para a sua preparacao
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE59710417D1
(de)
|
1996-03-15 |
2003-08-14 |
Novartis Ag |
N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
|
JP3370340B2
(ja)
|
1996-04-12 |
2003-01-27 |
ワーナー―ランバート・コンパニー |
チロシンキナーゼの不可逆的阻害剤
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
BR9709959A
(pt)
|
1996-06-24 |
2000-05-09 |
Pfizer |
Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(fr)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
|
AU3693697A
(en)
|
1996-07-13 |
1998-02-09 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
ATE227283T1
(de)
|
1996-07-13 |
2002-11-15 |
Glaxo Group Ltd |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
KR20000067904A
(ko)
|
1996-07-18 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
매트릭스 메탈로프로테아제의 포스피네이트계 억제제
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
EP1947183B1
(fr)
|
1996-08-16 |
2013-07-17 |
Merck Sharp & Dohme Corp. |
Antigène de surface de cellule de mammifère; agents chimiques relatifs
|
DK0938486T3
(da)
|
1996-08-23 |
2008-07-07 |
Novartis Ag |
Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
EP0929553B1
(fr)
|
1996-10-02 |
2005-03-16 |
Novartis AG |
Derives de pyrimidine et procedes de preparation de ces derniers
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
WO1998014449A1
(fr)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Derives de pyrazole condenses et procedes pour leur preparation
|
EP0837063A1
(fr)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
Dérivés de 4-aminoquinazoline
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
CA2277100C
(fr)
|
1997-01-06 |
2005-11-22 |
Pfizer Inc. |
Derives de sulfone cyclique
|
CN1113862C
(zh)
|
1997-02-03 |
2003-07-09 |
辉瑞产品公司 |
芳基磺酰氨基异羟肟酸衍生物
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
NZ336836A
(en)
|
1997-02-11 |
2001-02-23 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(fr)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Derives de quinoxaline tricyclique utiles en tant qu'inhibiteurs de proteine tyrosine kinase
|
ATE263147T1
(de)
|
1997-08-08 |
2004-04-15 |
Pfizer Prod Inc |
Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
|
WO1999020758A1
(fr)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
ATE430149T1
(de)
|
1998-03-04 |
2009-05-15 |
Bristol Myers Squibb Co |
Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
TR200003514T2
(tr)
|
1998-05-29 |
2002-05-21 |
Sugen Inc. |
Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
AU760020B2
(en)
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
DK1004578T3
(da)
|
1998-11-05 |
2004-06-28 |
Pfizer Prod Inc |
5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
|
EP1158985B1
(fr)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
|
ES2272268T3
(es)
|
1999-03-05 |
2007-05-01 |
Metabasis Therapeutics, Inc. |
Nuevos profarmacos que contienen fosforo.
|
ATE329596T1
(de)
|
1999-03-30 |
2006-07-15 |
Novartis Pharma Gmbh |
Phthalazinderivate zur behandlung von entzündlicher erkrankungen
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
US6413932B1
(en)
|
1999-06-07 |
2002-07-02 |
Immunex Corporation |
Tek antagonists comprising soluble tek extracellular binding domain
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
EP1212331B1
(fr)
|
1999-08-24 |
2004-04-21 |
Ariad Gene Therapeutics, Inc. |
Analogues d'epirapamycine-28
|
NZ518028A
(en)
|
1999-11-05 |
2004-03-26 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
ATE514676T1
(de)
|
1999-11-24 |
2011-07-15 |
Sugen Inc |
Ionisierbare indolinon derivate und deren verwendung als ptk liganden
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
AU2001247219B2
(en)
|
2000-02-25 |
2007-01-04 |
Immunex Corporation |
Integrin antagonists
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
SI2311825T1
(sl)
|
2000-12-21 |
2016-02-29 |
Novartis Ag |
Pirimidinamini kot angiogenetski modulatorji
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
US20040214798A1
(en)
|
2003-04-22 |
2004-10-28 |
Longqin Hu |
Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation
|
NZ543654A
(en)
|
2003-05-23 |
2009-05-31 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
MXPA06000117A
(es)
|
2003-07-08 |
2006-04-27 |
Novartis Ag |
Uso de rapamicina y derivados de rapamicina para el tratamiento de perdida osea.
|
EP1660126A1
(fr)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
WO2005016252A2
(fr)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Macrocycles contenant du phosphore
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
CN1839133A
(zh)
|
2003-08-22 |
2006-09-27 |
阿文尼尔药品公司 |
作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
JP2008515984A
(ja)
|
2004-10-13 |
2008-05-15 |
ワイス |
Pi3k阻害剤としての17−ヒドロキシワートマニンの類似体
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
CN105315373B
(zh)
|
2005-05-09 |
2018-11-09 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CA2622870A1
(fr)
|
2005-09-20 |
2007-03-29 |
Pfizer Products Inc. |
Formes de dosage et procedes de traitement utilisant un inhibiteur de la tyrosine kinase
|
WO2007133822A1
(fr)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Anticorps anti-gitr destinés au traitement du cancer
|
CA2671782C
(fr)
|
2006-12-07 |
2017-01-10 |
F. Hoffmann-La Roche Ag |
Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation
|
WO2009009116A2
(fr)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Thérapies combinées utilisant des molécules de liaison au gitr
|
PE20140100A1
(es)
|
2007-09-12 |
2014-02-12 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
|
CN101909631B
(zh)
|
2007-10-25 |
2012-09-12 |
健泰科生物技术公司 |
制备噻吩并嘧啶化合物的方法
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
RU2646139C1
(ru)
|
2009-09-03 |
2018-03-01 |
Мерк Шарп И Доум Корп. |
Анти-gitr-антитела
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
CN105693861A
(zh)
|
2009-12-29 |
2016-06-22 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
EP2696682B1
(fr)
|
2011-04-13 |
2018-03-21 |
Innovimmune Biotherapeutics, Inc. |
Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
JP6399660B2
(ja)
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
CA2904393A1
(fr)
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Inhibiteurs covalents de k-ras g12c
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
EP3636639A1
(fr)
|
2013-10-10 |
2020-04-15 |
Araxes Pharma LLC |
Inhibiteurs de kras g12c
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049565A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions et procédés pour inhiber la ras
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049524A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Krasの縮合三環系インヒビターおよびその使用の方法
|
WO2016209996A1
(fr)
|
2015-06-23 |
2016-12-29 |
University Of Oregon |
Hétérocycles contenant du phosphore et procédé de production et d'utilisation
|
EP3325447A1
(fr)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Composés de quinazoline substitués et leur utilisation en tant qu'inhibiteurs de protéines kras, hras et/ou nras mutantes g12c
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356354A1
(fr)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibiteurs de protéines kras portant la mutation g12c
|
WO2017058902A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058792A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
WO2017058768A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
AU2016355433C1
(en)
|
2015-11-16 |
2021-12-16 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
AU2017266911B2
(en)
|
2016-05-18 |
2021-09-02 |
Array Biopharma, Inc. |
KRas G12C inhibitors
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
BR112019012976A2
(pt)
|
2016-12-22 |
2019-12-31 |
Amgen Inc |
inibidores de kras g12c e métodos de uso dos mesmos
|
CN110382483A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的n-杂环化合物及其使用方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3788053A1
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
US20210130352A1
(en)
|
2018-06-21 |
2021-05-06 |
Janssen Pharmaceutica Nv |
Oga inhibitor compounds
|
EP3810586A1
(fr)
|
2018-06-21 |
2021-04-28 |
Janssen Pharmaceutica NV |
Composés inhibiteurs d'oga
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MA55136A
(fr)
|
2018-11-19 |
2022-02-23 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
KR20210121168A
(ko)
|
2019-01-29 |
2021-10-07 |
브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. |
복소환식 화합물인 벤조피리돈 및 그 사용
|
EP3738593A1
(fr)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosage d'inhibiteur de kras pour le traitement de cancers
|
US20220235045A1
(en)
|
2019-05-21 |
2022-07-28 |
Amgen Inc. |
Solid state forms
|
CR20210665A
(es)
|
2019-05-21 |
2022-01-25 |
Amgen Inc |
Formas en estado sólido
|
EP4048671A1
(fr)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
|